June 05, 2025

Gene Therapy for Stargardt Advances to Trial

VeonGen announces new name and progress in its VG801 clinical program, which targets genetic mutations linked to Stargardt disease.

Retinal Physician

June 03, 2025

Presbyopia Drop Gets FDA New Drug Application Approval

The FDA has set a Prescription Drug User Fee Act (PDUFA) date of January 28, 2026, for the drug.

Optometric Management

May 20, 2025

FDA Releases Guidance to Accelerate Generic Drugs

The new guidance is intended to “foster drug product development, ANDA submission and approval, and ultimately provide increased access to generic drugs."

Conexiant

November 15, 2024

Eyenovia Halts Eye Drug Trial

Eyenovia's late-stage study for near-sightedness in children with an experimental drug-device combination has been discontinued after failing to slow myopia progression, leading to consideration of strategic alternatives.

Reuters

April 24, 2025

FDA Rejects Extended Dosing Intervals for Eylea HD

The agency did not agree with Regeneron’s proposal to add dosing intervals greater than every 16 weeks, the maximum interval currently indicated for aflibercept 8 mg injections.

Retinal Physician

August 27, 2024

PCPs Play Important Role in Glaucoma Screening

“Recommendations from trusted primary providers have likely kept millions of individuals from becoming blind.”

Conexiant

February 13, 2025

FDA Approves Extended Label for Avacincaptad Pegol

The new label removes limitations on the duration of dosing.

Conexiant

January 16, 2025

LA County Fires Prompt Business Recovery Centers to Open

"Business owners can meet face-to-face with specialists to apply for disaster loans and access a wide range of resources to guide them through their recovery."

Optometric Management

December 16, 2024

Does Ozempic Double Eye Disease Risk?

Danish health authorities seek EU review of studies linking Novo Nordisk's Ozempic to rare eye condition in type 2 diabetes patients.

Reuters